These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 11837640

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

  • 3. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
    Hoban DJ, Bouchillon SK, Karlowsky JA, Johnson JL, Butler DL, Miller LA, Poupard JA.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
    [Abstract] [Full Text] [Related]

  • 4. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F, Giménez MJ, Marco F, Alou L, Aguilar L, Prieto J.
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M, Parra A, García-Calvo G, Ponte C, Giménez MJ, Aguilar L, Soriano F.
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH, Memish ZA, Shibl A, Elbashier A, Osoba A.
    East Mediterr Health J; 2005 Jun; 11(1-2):36-44. PubMed ID: 16532669
    [Abstract] [Full Text] [Related]

  • 9. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [Abstract] [Full Text] [Related]

  • 10. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P, Pascual A, Giménez MJ, García I, Aguilar L, Perea E.
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [Abstract] [Full Text] [Related]

  • 11. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
    Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 16. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J, Aguilar L, Fuentes F, Giménez MJ, Alou L, Dal-Ré R, Sörgel F, Frías J.
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [Abstract] [Full Text] [Related]

  • 17. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I, George JT.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
    Calvo A, Giménez MJ, Alou L, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2002 Aug; 20(2):144-6. PubMed ID: 12297365
    [No Abstract] [Full Text] [Related]

  • 20. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
    Heinemann B, Wisplinghoff H, Edmond M, Seifert H.
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.